Analysis of adverse drug reactions in remdesivir therapy using the Naranjo Algorithm

Penulis

  • Afifah Fauziyyah Universitas Bengkulu
  • Rani Sauriasari Universitas Indonesia
  • Ratika Rahmasari Universitas Indonesia
  • Hindun Wilda Risni Universitas Indonesia
  • Puji Astuti Rumah Sakit Umum Daerah Cengkareng

DOI:

https://doi.org/10.54957/ijhs.v6i1.2049

Kata Kunci:

Causality Analysis, COVID-19, Drug Safety, Remdesivir

Abstrak

Research on the safety of remdesivir in Indonesian subjects for COVID-19 therapy is still limited and has yielded different results. None of these studies have used the Naranjo algorithm to analyze the causality of remdesivir safety. This study aimed to evaluate the safety of remdesivir in patients with severe COVID-19. Data were collected using medical records of patients with severe COVID-19 at Cengkareng Regional Hospital, Indonesia. The study was conducted retrospectively with a cohort study design. Subjects consisted of the remdesivir group (n=80) and the non-remdesivir group (n=80). Adverse drug reactions (ADRs) were observed, and causality analysis of ADRs was performed using the Naranjo algorithm. The study found 10 ADRs experienced by patients during treatment. ADRs were more common in the remdesivir group than in the non-remdesivir group (58.8% vs 53.8%; p=0.633). Significant events with a high proportion in the remdesivir group were increased ALT (p=0.037) and lymphopenia (p=0.01). Hepatotoxic reactions associated with remdesivir use were associated with P-glycoprotein (P-gp) inhibitor interactions. Decreased lymphocyte counts were closely related to the clinical condition of the study subjects, namely patients with severe COVID-19, and this condition was associated with a poor prognosis. Increased blood triglycerides, lymphopenia, and decreased estimated glomerular filtration rate (eGFR) were categorized as probable. Meanwhile, nausea, melena, QT interval prolongation, increased ALT, increased AST, hyperuricemia, and neutrophilia were categorized as quite possible. The results of this study can be concluded that remdesivir causes liver dysfunction manifested by increased ALT values ​​and decreased lymphocyte counts, which worsen the condition of patients with severe COVID-19.

Referensi

Buckland, M. S., Galloway, J. B., Fhogartaigh, C. N., Meredith, L., Provine, N. M., Bloor, S., Ogbe, A., Zelek, W. M., Smielewska, A., Yakovleva, A., Mann, T., Bergamaschi, L., Turner, L., Mescia, F., Toonen, E. J. M., Hackstein, C. P., Akther, H. D., Vieira, V. A., Ceron-Gutierrez, L., Thaventhiran, J. E. D. (2020). Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case report. Nature Communications, 11(1). https://doi.org/10.1038/s41467-020-19761-2

Burhan, E., Susanto, A. D., Nasution, S. aman, Ginanjar, E., Pitoyo, C. W., Susilo, A., Firdaus, I., Santoso, A., Juzar, D. A., Arif, S. K., Wulung, N. G. . L., Adityaningsih, D., Syam, A. F., Rasmin, M., Regganis, I., Sukrisman, L., Damayanti, T., Wiyono, W. H., Prasenohadi, … Dharmawan. (2022). COVID-19 (4th ed.). PDPI, PERKI, PAPDI, PERDATIN, IDAI.

Doi, Y., Kondo, M., Matsuyama, A., Ando, M., Kuwatauka, Y., & Ishihara, T. (2020). Preliminary Report of the Favipiravir Observational Study in Japan. The Japanese Association for Infectious Diseases, 1–6. https://www.kansensho.or.jp/uploads/files/topics/2019ncov/covid19_casereport_en_200529.pdf

Grein, J., Ohmagari, N., Shin, D., Diaz, G., Asperges, E., Castagna, A., Feldt, T., Green, G., Green, M. L., Lescure, F.-X., Nicastri, E., Oda, R., Yo, K., Quiros-Roldan, E., Studemeister, A., Redinski, J., Ahmed, S., Bernett, J., Chelliah, D., … Flanigan, T. (2020). Compassionate Use of Remdesivir for Patients with Severe Covid-19. New England Journal of Medicine, 382(24), 2327–2336. https://doi.org/10.1056/nejmoa2007016

Joo, E. J., Ko, J. H., Kim, S. E., Kang, S. J., Baek, J. H., Heo, E. Y., Shi, H. J., Eom, J. S., Choe, P. G., Bae, S., Ra, S. H., Kim, D. Y., Kim, B. N., Kang, Y. M., Kim, J. Y., Chung, J. W., Chang, H. H., Bae, S., Cheon, S., … Peck, K. R. (2021). Clinical and Virologic Effectiveness of Remdesivir Treatment for Severe Coronavirus Disease 2019 (COVID-19) in Korea: a Nationwide Multicenter Retrospective Cohort Study. Journal of Korean Medical Science, 36(11), 1–13. https://doi.org/10.3346/jkms.2021.36.e83

Kalligeros, M., Tashima, K. T., Mylona, E. K., Rybak, N., Flanigan, T. P., Farmakiotis, D., Beckwith, C. G., Sanchez, M., Neill, M., Johnson, J. E., Garland, J. M., Aung, S., Byrd, K. M., O’Brien, T., Pandita, A., Aridi, J., Macias Gil, R., Larkin, J., Shehadeh, F., & Mylonakis, E. (2020). Remdesivir Use Compared With Supportive Care in Hospitalized Patients With Severe COVID-19: A Single-Center Experience. Open Forum Infectious Diseases, 7(10), 1–8. https://doi.org/10.1093/ofid/ofaa319

Lukito, J. I. (2020). Tinjauan Antivirus untuk Terapi COVID-19. 340 Cdk-286, 47(5), PP:342.

Moon, A. M., & Barritt, A. S. (2021). Elevated Liver Enzymes in Patients with COVID-19: Look, but Not Too Hard. Digestive Diseases and Sciences, 66(6), 1767–1769. https://doi.org/10.1007/s10620-020-06585-9

Prozan, L., Shusterman, E., Ablin, J., Mitelpunkt, A., Weiss-Meilik, A., Adler, A., Choshen, G., & Kehat, O. (2021). Prognostic value of neutrophil-to-lymphocyte ratio in COVID-19 compared with Influenza and respiratory syncytial virus infection. Scientific Reports, 11(1), 1–8. https://doi.org/10.1038/s41598-021-00927-x

Putra, R. J. S., Achmad, A., & Pramestutie, H. R. (2017). Kejadian Efek Samping Potensial Terapi Obat Anti Diabetes Pada Pasien Diabetes Melitus Berdasarkan Algoritme Naranjo. Pharmaceutical Journal of Indonesia, 2(2), 45–50. https://doi.org/10.21776/ub.pji.2017.002.02.3

Rabaan, A. A., Tirupathi, R., Sule, A. A., Aldali, J., Mutair, A. Al, Alhumaid, S., Muzaheed, Gupta, N., Koritala, T., Adhikari, R., Bilal, M., Dhawan, M., Tiwari, R., Mitra, S., Emran, T. Bin, & Dhama, K. (2021). Viral dynamics and real-time rt-pcr ct values correlation with disease severity in covid-19. Diagnostics, 11(6). https://doi.org/10.3390/diagnostics11061091

Rusli. (2018). Farmasi Klinik (2018th ed.). Kementerian Kesehatan RI. Pusat Pendidikan Sumber Daya Manusia Kesehatan.

Sastroasmoro. (2011). Dasar-Dasar Metodologi Penelitian Klinis. In Sagung Seto. Sagung Seto.

Vitiello, A., La Porta, R., D’Aiuto, V., & Ferrara, F. (2021). The risks of liver injury in COVID-19 patients and pharmacological management to reduce or prevent the damage induced. Egyptian Liver Journal, 11(1). https://doi.org/10.1186/s43066-021-00082-y

Wang, Y., Zhang, D., Du, G., Du, R., Zhao, J., Jin, Y., Fu, S., Gao, L., Cheng, Z., Lu, Q., Hu, Y., Luo, G., Wang, K., Lu, Y., Li, H., Wang, S., Ruan, S., Yang, C., Mei, C., … Wang, C. (2020). Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. The Lancet, 395(10236), 1569–1578. https://doi.org/10.1016/S0140-6736(20)31022-9

Unduhan

Diterbitkan

09-02-2026

Cara Mengutip

Fauziyyah, A., Sauriasari, R., Rahmasari, R., Risni, H. W., & Astuti, P. (2026). Analysis of adverse drug reactions in remdesivir therapy using the Naranjo Algorithm. Indonesian Journal of Health Science, 6(1), 118–127. https://doi.org/10.54957/ijhs.v6i1.2049

Terbitan

Vol 6 No 1 (2026)

Bagian

Articles

Lisensi

Hak Cipta (c) 2026 Afifah Fauziyyah, Rani Sauriasari, Ratika Rahmasari, Hindun Wilda Risni, Puji Astuti

Creative Commons License

Artikel ini berlisensi Creative Commons Attribution 4.0 International License.